STX
NEUTRALShield Therapeutics Wins Prestigious Branding Award
The pharmaceutical company has been recognized for its successful brand transformation of its lead product ACCRUFeR®.
Shield Therapeutics
10.25GBX
0.00%
Market Cap
108.83M
Volume
1.33M
40% of avg
P/E Ratio
-3416.67
EPS (TTM)
-0
Beta
1.76
Day Range
9.80p - 10.50p
52 Week Range
2.10p10.25p12.50p
10.25p
Upcoming Events
STX
GOODShield Therapeutics Secures Improved Debt Financing Terms
The healthcare company has amended its senior secured debt financing, securing improved terms and additional capital to support future growth and M&A.
STX
NEUTRALShield Therapeutics Initiates Phase II Trial of ACCRUFER for PAH in Japan
The pharmaceutical company has initiated a Phase II clinical trial for its drug candidate ACCRUFER to treat Pulmonary Arterial Hypertension in Japan.
STX
NEUTRALShield Therapeutics Presents Positive Pediatric PK Data for ACCRUFeR
The healthcare company will present positive pharmacokinetic results from a pediatric clinical trial of its iron deficiency treatment at an upcoming medical conference.
STX
GOODShield Therapeutics Receives Regulatory Approval for ACCRUFeR® in South Korea
The healthcare company has received regulatory approval for its iron deficiency treatment ACCRUFeR® in South Korea, marking an important milestone in expanding access to the product.
STX
VERY GOODShield Therapeutics Reports Strongest Q3 2025 Performance to Date
The specialty pharmaceutical company reported its strongest quarterly performance to date, driven by robust growth in ACCRUFeR® revenues and prescription volumes.
STX
NEUTRALShield Therapeutics Grants Share Options to CEO
The pharmaceutical company has granted share options to its CEO as part of the annual equity grant.
STX
NEUTRALShield Therapeutics Presents Positive Pediatric Trial Results for ACCRUFeR
The healthcare company has presented positive efficacy and tolerability results from a pediatric trial of its iron deficiency treatment.
STX
BADShield Therapeutics Raises £1.5 Million Through Discounted Placing
The healthcare company has raised £1.5 million through a discounted share placing, signaling potential challenges in attracting investors at the current valuation.
STX
NEUTRALShield Therapeutics' ACCRUFeR® granted Priority Review by FDA for adolescent use
The healthcare company has received priority review from the FDA for expanding the use of its iron deficiency treatment to adolescents.